The outcome wasn't the same for AB InBev rival Molson Coors Beverage Company (TAP), which saw shares tumble when the brewer ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Eli Lilly & Co has experienced a significant stock price drop of 10.58% over the past week, despite delivering impressive first-quarter results for 2025. The company’s revenue s ...

EPAM Systems beat quarterly results, raised its outlook, and announced a new CEO ... after profit and sales declined. Shares of Eli Lilly (LLY) and other pharmaceutical firms fell on a report ...

The head of drugmaker Eli Lilly, which sells the popular ... tariffs currently in effect do not materially change Lilly’s 2025 financial outlook,” he said. “However, the expansion of tariffs ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Eli Lilly produces brand ... says Palantir's impressive growth outlook suggests more upside ahead. CFRA has a "buy" rating and $128 price target for PLTR stock, which closed at $117.30 on May ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

The stock should perform well beyond 2030 thanks to its impressive innovative abilities. With a constellation of ...